SynthesisAnnals of medicine2026
Janus kinase inhibitors in the management of lichen planus: a systematic review.
Synthesis in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesLichen planus (LP) is a chronic, lymphocytic, inflammatory skin disorder that can affect the skin, hair follicles, nails, and mucous membranes. It has limited treatment options. The pathogenesis of LP includes inflammation driven by interferons and the Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling pathway. Thus, Janus kinase inhibitors (JAKi) have been proposed as a viable therapeutic approach for LP. JAKi have recently been approved to treat some lymphocytic skin disorders such as alopecia areata and atopic dermatitis. The purpose of the systematic review was to assess the effects of JAKi on LP. MATERIALS AND
methodsWe searched PubMed, Scopus, and Google Scholar and included all studies published between January 2015 and May 2024 that assess the clinical effects of JAKi on lichen planus, including cutaneous and mucosal/adnexal variants. The risk of bias in included studies was assessed using Joanna Briggs Institute (JBI) tools, classifying bias as low, moderate and high concerns.
resultsA total of 57 full-text publications were evaluated, of which 34 papers were excluded because they did not match the criteria. Therefore, this systematic review included 23 papers, seven of them were case series and the remaining 16 were case reports. There were 13 papers on tofacitinib, six on baricitinib, and two papers each on ruxolitinib and upadacitinib.
conclusionSeveral case series and case reports have shown beneficial effects of JAK inhibitors to treat LP. Few patients had minor adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.